Psychiatry Roundup: Telehealth Pill Conviction, Digital Schizophrenia Therapy, AI Worries
A Michigan physician was convicted of illegally distributing more than 2 million stimulant pills through a telehealth ADHD platform. The FDA cleared a prescription digital therapeutic for negative schizophrenia symptoms and asked for public input on ibogaine drug development. The psychiatry roundup also noted rising AI-related anxiety in therapy, mental health support for airline workers, and studies on psilocybin, Medicaid addiction treatment, traffic noise, and depression.
A Michigan physician, Jonathan Decker, was found guilty of unlawfully supplying over two million stimulant pills, including Adderall, through a telehealth ADHD service called Done. Separately, regulators cleared Motivista, a prescription digital therapy, to supplement outpatient care for schizophrenia’s negative symptoms, and opened a comment period on ibogaine research.
Other items in the roundup included a survey showing greater public backing for civil rights protections for people with severe physical disabilities than for those with mental illness or addiction. Reports also covered AI-related therapy anxiety, Senate measures aiding airline workers’ mental health, psilocybin and unmet depression treatment needs, Medicaid addiction care gaps for young people, traffic noise and depression risk, Phil Mickelson’s treatment, and prison heat-linked suicides.
The conviction could prompt tighter oversight of telehealth ADHD prescribing, potentially affecting patients who rely on remote care and clinicians balancing access with misuse prevention. Clearance of a digital schizophrenia therapy may expand non-drug options, though adoption and coverage may vary. Rising AI-related therapy concerns, airline-worker mental health measures, and Medicaid addiction treatment gaps may shape how employers, insurers, and public programs respond. Together, these developments could influence trust, access, and stigma for people seeking psychiatric and addiction care.